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Summary
BACKGROUND: The clinical efficacy and safety of combi-
nation therapy with acetylcholinesterase inhibitor (AChEI)
and memantine compared to AChEI or memantine alone
in patients with Alzheimer’s disease is inconclusive. AIMS
OF THE STUDY. We conducted a systematic review and
meta-analysis of randomised controlled trials (RCTs) com-
paring the clinical efficacy and safety of combination ther-
apy of AChEI and memantine to monotherapy with either
substance in patients with moderate to severe Alzheimer's
disease (Mini-Mental State Examination score is <20).
METHODS: We systematically searched EMBASE, Med-
line and CENTRAL until February 2018 for eligible RCTs.
We pooled the outcome data using inverse variance
weighting models assuming random effects, and as-
sessed the quality of evidence (QoE) according to the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE).
RESULTS: We included nine RCTs (2604 patients). At
short-term follow-up (closest to 6 months), combination
therapy compared to AChEI monotherapy had a signifi-
cantly greater effect on cognition than AChEI monothera-
py (standardised mean difference [SMD] 0.20, 95% con-
fidence interval [CI] 0.05 to 0.35, 7 RCTs, low QoE) and
clinical global impression (SMD −0.15, 95% CI −0.28 to
−0.01, 4 RCTs, moderate QoE), but not on activities of dai-
ly living (SMD 0.09, 95% CI −0.01 to 0.18, 5 RCTs, mod-
erate QoE) or behavioural and psychological symptoms of
dementia (mean difference −3.07, 95% CI −6.53 to 0.38,
6 RCT, low QoE). There was no significant difference in
adverse events (relative risk ratio 1.05, 95% CI 0.98 to
1.12, 4 RCTs, low QoE). Evidence for long-term follow-up
(≥ 9 months) or nursing home placement was sparse. Only
two studies compared combination therapy with meman-
tine monotherapy.
CONCLUSIONS: Combination therapy had statistically
significant effects on cognition and clinical global impres-
sion. The clinical relevance of these effects is uncertain.
The overall QoE was very low. With the current evidence,
it remains unclear whether combination therapy adds any
benefit. Large pragmatic RCTs with long-term follow-up
and focus on functional outcomes, delay in nursing home
placement and adverse events are needed.
Keywords: Alzheimer’s, dementia, drug treatment, me-
mantine, cholinesterase inhibitor
Introduction
Alzheimer’s disease is a serious neurocognitive disorder
characterised by a progressive decline of cognitive func-
tions and memory (disturbances in attention, executive
functions, learning and memory, speech, perceptual-motor
ability and social cognition) [1, 2]. The resulting disabili-
ties can limit independent daily living [2]. Alzheimer’s dis-
ease is the most common form of dementia, which affects
millions of elderly people worldwide and is classified as a
public health priority by the WHO [3].
Pharmaceutical therapy of Alzheimer’s disease typically
includes acetylcholinesterase inhibitors (AChEIs), which
inhibit chemical neurotransmitter breakdown. Cochrane
reviews have reported that AChEIs may reduce disease
progression, i.e. delay the decline in cognition and activi-
ties of daily living, but also cause adverse events, most fre-
quently mild, such as diarrhoea, nausea or vomiting [4–6].
The N-methyl-D-aspartate receptor antagonist memantine
is an alternative pharmaceutical treatment option and has
been reported to delay Alzheimer’s disease progression
with side effects similar to those of a placebo [7].
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AChEIs are approved for dementia irrespective of the
severity, but are commonly administered to patients with
mild to moderate Alzheimer’s disease (Mini-Mental State
Examination, MMSE score of around 26 to 10), while
memantine is approved for moderate to severe dementia
(MMSE score ≤19). Combination therapy is frequently
used in Europe, the United States (US) and Switzerland
in patients with moderate to severe Alzheimer's disease
(MMSE score 19 to 10), especially if patient cognition de-
teriorates. In contrast to the practice in other countries, the
Swiss mandatory basic health insurance does not cover the
combination therapy [8]. This means that in Swiss clini-
cal practice both substances can be prescribed in combi-
nation, but only one drug will be reimbursed and the oth-
er is paid for by the patient. Memantine is often added
to an ongoing AChEI therapy with donepezil, galantamine
or rivastigmine. Fixed combination products for combined
therapy of AChEI and memantine have been approved by
the US Food and Drug Administration (FDA), but not
by the European Medicines Agency (EMA) [9, 10] and
Switzerland. Previous systematic reviews comparing the
efficacy of combination therapy with monotherapy over-
looked a number of relevant studies [11], included studies
of mildly severe dementia [12], for which memantine is not
approved, or confined their assessment by using a selec-
tive comparator regimen, i.e. donepezil [13]. The objective
of the present systematic review and meta-analysis was to
comprehensively assess the clinical efficacy and safety of
all combination therapy modalities compared to monother-
apy with AChEI or memantine in patients with moderate to
severe Alzheimer’s disease. The present systematic review
ABBREVIATIONS:
AA-NIA Alzheimer's Association and the National Institute on
Ageing
AChEI acetylcholinesterase inhibitor
CI confidence intervals
ADAS-Cog
Alzheimer’s Disease Assessment Scale, cognitive sub-
scale
DSM Diagnostic and Statistical Manual of Mental Disorders
EMA European Medicines Agency
FDA Food and Drug administration
GRADE Grading of Recommendations Assessment, Develop-
ment and Evaluation
ICD International Classification of Diseases
IPD individual patient data
LOCF last observation carried forward
MD mean difference
MMSE Mini-Mental State Examination
NINCDS-ADRDA
National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer's Disease and
Related Disorders Association
NPI Neuropsychiatric Inventory
QoE quality of evidence
RCTs randomised controlled trials
RR relative risk ratio
SMB Swiss Medical Board
SMD standardised mean difference
US United States
WHO World Health Organization
stems from the clinical effectiveness section of a Health
Technology Assessment report commissioned to us by the
Swiss Medical Board (SMB) [14]. For the present report,
we updated the literature search and aimed to add newly
published studies.
Methods
Search and study selection
We registered the protocol of this systematic review with
PROSPERO (CRD42018079508). We searched MED-
LINE and EMBASE (via OvidSP), and the Cochrane cen-
tral register of controlled trials (Central) from inception
until 5 February 2018. We conducted a top-up search via
PubMed to identify not yet indexed publications in MED-
LINE. The search strategy (see appendix, supplement 1)
combined search terms for dementia and memantine, but
did not contain terms for AChEI; these would have only
complicated the search strategy without adding relevant ar-
ticles, as combination therapy with memantine was the in-
tervention of interest. We used the optimised randomised
controlled trial (RCT) filter with regard to sensitivity and
specificity in EMBASE [15], and the sensitivity- and pre-
cision-maximising filter in MEDLINE [16]. After removal
of duplicate publications, two reviewers independently
screened the titles and abstracts of the identified records
for potentially eligible studies. Discrepant screening re-
sults were discussed and resolved by consensus. Subse-
quently, two reviewers independently screened the full text
articles of the potentially relevant studies for eligible
RCTs. Discrepant screening results were discussed and re-
solved by consensus or third-party arbitration.
Our inclusion criteria for relevant studies were:
1. The diagnosis of Alzheimer’s disease was based on
DSM-III, DSM-III-R, DSM-IV, DSM-5, ICD-9,
ICD-10, AA-NIA or NINCDS-ADRDA. We allowed
for patient populations with mixed forms of dementia,
i.e. with vascular dementia, but studies including sole-
ly patients with vascular dementia were not eligible.
2. Alzheimer’s disease was moderate to severe (MMSE
<20). RCTs with mixed populations including mild
severity were eligible if at least 80% of the population
was reported to be moderate or severe. If severity was
not reported, we approximated the proportion of pa-
tients with mild dementia based on the reported base-
line mean MMSE and its distribution.
3. Combination therapy (AChEI plus memantine) was
compared with AChEI monotherapy or memantine
monotherapy.
4. The study design was an RCT or quasi-RCT.
5. The publications were in English, German, French or
Italian.
Since we did not expect patients to be AChEI treatment
naïve, we set no restriction regarding precedent or ongoing
AChEI or memantine treatment.
Study outcomes and statistical analysis
We predefined outcomes with clinical experts (AUM and
RWK) and categorised them as critical or important ac-
cording to the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) [17]. Those out-
Systematic review Swiss Med Wkly. 2019;149:w20093
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 2 of 12
comes we thought most relevant for decision-making we
classified as “critical”, and the lowest quality of the evi-
dence available for any of these outcomes is the basis for
judging the overall quality of the evidence [18]. We pre-
defined cognition, activities of daily living, clinical glob-
al impression, behavioural and psychological symptoms of
dementia and delay of nursing home placement (only rel-
evant to studies starting in an ambulatory setting) as criti-
cal outcomes. Withdrawal from the study, adverse events,
caregiver burden or distress and quality of life were clas-
sified as important outcomes [17]. One reviewer extract-
ed the data on study characteristics and outcomes into a
standardised, pilot-tested form, a second reviewer checked
it. Discrepancies were resolved by discussion or third-par-
ty arbitration. Continuous outcome data were extracted as
means and standard deviations for each treatment group at
follow-up. If means were not available at follow-up, mean
changes were extracted from the baseline. Because out-
comes were assessed by different instruments, we ranked
them hierarchically and decided which data to extract (see
appendix, supplement 2). In addition to the pre-specified
protocol registered at PROSPERO (CRD42018079508),
we also extracted information on responder analyses of the
individual RCTs. Outcome data were summarised quan-
titatively in a meta-analysis by using inverse variance
weighting models assuming random effects [19]. The
analyses were performed using Review Manager (Version
5.3.5). Two follow-up time points were defined based on
expert opinions (AUM and RWK); hence, meta-analyses
were done for short-term (closest to 6 months) and long-
term follow-up (at 9 months or the latest available follow-
up). In case of continuous data, mean treatment group dif-
ferences were pooled, either on the original scale or by
using standardised mean differences (SMD) [20, 21].
One reviewer assessed the internal validity (risk of bias)
[21] of each trial and the quality of evidence (QoE) [22]
of every effect estimate for each outcome, which was then
checked by a second reviewer. Discrepancies were re-
solved by discussion or third-party arbitration. The quality
of evidence was judged according to GRADE [22].
Results
We identified nine eligible RCTs (fig. 1, table 1). Seven
RCTs assessed combination therapy versus AChEI
monotherapy (Araki 2014 [23], EXPECT 2011 [26, 27],
Grossberg 2013 [28], Herrmann 2013 [29], Porsteinsson
2008 [30], Tariot 2004 [31–35] and Wilkinson 2012 [37]),
one RCT compared combination therapy versus meman-
tine monotherapy (Shao 2015 [36]) and one four-armed
RCT assessed combination therapy with both monothera-
pies with a two-by-two factorial study design (DOMINO-
AD 2012 [24, 25]). Since DOMINO-AD 2012 unblinded
patients and physicians after 52 weeks, we did not include
later follow-up time-points.
Most RCTs included a mix of patients with moderate to
severe Alzheimer’s disease. Although the EXPECT 2011
and Porsteinsson 2008 trials included patients with mild to
moderate Alzheimer’s disease, and the two trials Wilkin-
son 2012 and Shao 2015 did not report on disease severity,
we estimated that at least 80% of patients in these trials had
moderate Alzheimer’s disease based on reported baseline
MMSE in these trials.
Araki 2014, DOMINO-AD 2012, Herrmann 2013, Gross-
berg 2013, Porsteinsson 2008 and Tariot 2004 reported that
patients were on AChEI therapy for at least 3 months. The
EXPECT 2011 trial recruited AChEI treatment-naïve pa-
tients whose dosage of the transdermal rivastigmine patch
was titrated depending on tolerability until reaching a sta-
ble dose prior to randomisation. Wilkinson 2012 did not
report on precedent AChEI therapy. The EXPECT 2011
study was the only study to apply a transdermal patch as
route of administration. In the two trials comparing combi-
nation versus memantine monotherapy, one study (DOMI-
NO-AD 2012) reported a 4-week period during which
AChEI was decreased to 0 mg (placebo) and memantine
therapy was initiated in parallel with 5-mg weekly incre-
ments of memantine. The other study (Shao 2015) reported
a one week ‘wash-out phase’ (the authors did not specify
of what) before the study treatment initiation.
Combination therapy versus AChEI monotherapy
At short-term follow-up, combination therapy had a sig-
nificantly better effect than AChEI monotherapy on cogni-
tion (SMD 0.20, 95% CI 0.05 to 0.35, I2 = 62%, 7 RCTs,
low QoE, fig. 2) and clinical global impression (SMD
−0.15, 95% CI −0.28 to −0.01, I2 = 45%, 4 RCTs, mod-
erate QoE, fig. 3). There was no significant difference for
activities of daily living (SMD 0.09, 95% CI −0.01 to 0.18,
I2 = 0%, 5 RCTs, moderate QoE, fig. 4) or behavioural
and psychological symptoms (MD −3.07, 95% CI −6.53
to 0.38, I2 = 85%, 6 RCT, low QoE, fig. 5). Caregiver
burden or distress was only reported by Araki 2014 and
DOMINO-AD 2012. Araki 2014 reported reduced caregiv-
er burden or distress with combination therapy (Japanese
version of the Zarit Burden Interview scale mean scores
±SD: −0.33±10.87 versus 18.23±7.89) and DOMINO-AD
2012 reported a non-significant estimated average differ-
ence over all follow-up time points (−0.5, 99% CI −1.3 to
0.3, mixed regression model analysis, up to 52 weeks). On-
ly DOMINO-AD 2012 reported on quality of life (Demen-
tia Quality of Life), and the estimated difference over all
follow-up time points was not significantly different (2.0,
99% CI –2.3 to 6.2, mixed regression model analysis, up to
52 weeks). Only Tariot 2004 reported ‘response rates’ for
global impression based on CIBIC-plus, a 7-point scale of
change. Every change on this scale can be considered to be
clinically relevant [38]. At 24 weeks, Tariot 2004 report-
ed no worsening of global impression in 109 out of 198
(55%) patients in the combination therapy and 89 out of
197 (45%) patients in the AChEI monotherapy group. Tar-
iot 20014 did not report response rates for the other out-
comes. The other studies did not report response rates, al-
though EXPECT 2011 reported having assessed response
rates for all outcomes, but provided no results, and only
stated that no differences in response rates were found.
At short-term follow-up, the RR for experiencing at least
one adverse event (RR 1.05, 95% CI 0.98 to 1.12, I2 = 0%,
4 RCTs, low QoE, fig. 6) or withdrawal from the study (RR
0.89, 95% CI 0.72 to 1.11, I2 = 19%, low QoE, 6 RCTs, fig.
7) was not significantly different.
At long-term follow-up, there was no significant difference
in cognition (SMD 0.08, 95% CI −0.14 to 0.29, I2 = 0%,
2 RCTs, low QoE, fig. 2), activities of daily living (SMD
0.08, 95% CI −0.25 to 0.40, 1 RCT, low QoE, fig. 3), ad-
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verse events (RR 0.87, 95% CI 0.67 to 1.14, 1 RCT, very
low QoE, fig. 5) or the withdrawal rate (RR 0.87, 95% CI
0.67 to 1.14, 1 RCT, very low QoE, fig. 7). No other out-
comes were reported at long-term follow-up.
Two RCTs reported on nursing home placement. Herrmann
2013 reported that fewer patients, who received combina-
tion therapy, i.e. 2 of 182 (1.1%) versus 9 of 187 (4.8%),
and discontinued the trial due to nursing home placement
at short-term follow-up (24 weeks). However, the authors
did not report whether any patients who completed the trial
were placed in a nursing home. For the outcome of delay
in nursing home placement, DOMINO-AD 2012 reported
that the confidence intervals of the probabilities after com-
bination therapy overlapped with those after monothera-
py with donepezil (Kaplan-Meier estimates: 0.20, 95% CI
0.12 to 0.32 versus 0.21, 95% CI 0.12 to 0.33) at 12 months
of follow-up; hence, there was no difference. Outcomes on
delay in nursing home placement were not pooled, hence,
the QoE for the outcome delay in nursing home placement
was judged to be very low.
Figure 1: Article identification, inclusion and exclusion.
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Combination versus memantine monotherapy
At short- and long-term follow-up, there were no signifi-
cant differences for cognition (short follow-up: MD 1.32,
95% CI −0.44 to 3.08, I2 = 68%, 2 RCTs, very low QoE;
long follow-up: MD 0.80, 95% CI −1.01 to 2.61, 1 RCT,
low QoE) or activities of daily living (short follow-up:
SMD 0.06, 95% CI −0.55 to 0.68, I2 = 78%, 2 RCTs,
very low QoE; long follow-up: SMD 0.22, 95% CI −0.10
to 0.55, 1 RCT, low QoE). Only DOMINO-AD 2012 as-
sessed caregiver burden/distress and quality of life, and
reported a non-significant average difference over all FU
time-points from mixed regression model analysis (−0.6,
99% CI −1.3 to 0.2, up to 52 weeks and −0.9, 99% CI –5.2
to 3.4). Both RCTs did not report on clinical global impres-
sion, behavioural and psychological symptoms of demen-
tia, or reported response rates for any of the outcomes.
At short- and long-term follow-up, the RR for the number
of patients with at least one adverse event was not sta-
tistically significantly different (short follow-up: RR 1.40,
95% CI 0.60 to 3.27, 1 RCT, very low QoE; long follow-
up: RR 1.07, 95% CI 0.80 to 1.43, 1 RCT, very low QoE).
Withdrawals were only reported at long-term FU and RR
was not statistically significantly different (RR 0.56, 95%
CI 0.25 to 1.23, 1 RCT, very low QoE).
DOMINO-AD was the only study reporting on nursing
home placement. At 12 months, the confidence intervals
of the probabilities for nursing home placement after com-
bination therapy overlapped with those after memantine
monotherapy (Kaplan-Meier estimates: 0.21, 95% CI 0.12
to 0.33 versus 0.37, 95% CI 0.26 to 0.51).
Table 1: Overview of included studies.
Study ID [ref.] Country (setting) MMSE range Number randomised Intervention vs comparator Follow-up extract-
ed (weeks)
Araki 2014 [23] Japan (ambulatory, single cen-
tre)
Not reported 37 Memantine + donepezil vs donepezil 24
DOMINO-AD 2012 [24,
25]
UK (ambulatory, multicentre) 5–13 146 Memantine + donepezil vs donepezil + placebo 30, 52
150
EXPECT 2011 [26, 27] South Korea (ambulatory, multi-
centre)
10–20 172 Memantine + transdermal rivastigmine vs trans-
dermal rivastigmine
16
Grossberg 2013 (MEM-
MD-50) [28]
Argentina, USA, Mexico, Chile
(ambulatory, multicentre)
3–14 677 Memantine + AChEI vs AChEI 24
Herrmann 2013 [29] Canada (ambulatory, multicen-
tre)
5-15 369 Memantine + AChEI vs placebo + AChEI 24
Porsteinsson 2008
(MEM-MD-12) [30]
USA (ambulatory, multicentre) 10–22 433 Memantine + AChEI vs AChEI 24
Tariot 2004 (MEM-
MD-02) [31–35]
USA (ambulatory, multicentre) 5–14 404 Memantine + donepezil vs donepezil 24
Shao 2015 [36] China (not reported, single cen-
tre)
10–24 88 Memantine + donepezil vs memantine + ri-
vastigmine
vs memantine + galantamine vs memantine +
placebo
24
Wilkinson 2012 [37] France, Germany, Switzerland
and UK (ambulatory, multicen-
tre)
12–20 278 Memantine vs placebo (subgroups were includ-
ed for the report: memantine + AChEI vs place-
bo + AChEI)
52
AChEI = acetylcholinesterase inhibitor; MMSE = Mini-Mental State Examination
Figure 2: Cognition.
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Quality of evidence
The overall QoE for both comparisons, i.e. AChEI or me-
mantine monotherapy, were judged to be very low for
short- and long-term follow-up based on the QoE available
for the critical outcomes, where the lowest judgment de-
termines the overall QoE. At short-term follow-up with
AChEI monotherapy as comparator, the judgment of very
low quality of evidence of the outcome of delay in nursing
home placement led to an overall very low quality of evi-
dence. In all the other instances, the QoE was very low for
Figure 3: Clinical global impression.
Figure 4: Activities of daily living.
Figure 5: Behavioural and psychological symptoms of dementia.
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other critical outcomes as well (see appendix, supplement
3).
We did not conduct the pre-specified subgroup analyses for
any of the outcomes because too few trials were available.
Sensitivity analyses addressing differences between trials
in disease severity at baseline, type of instruments used for
assessing dementia, drug adherence, industry versus non-
industry sponsoring, AChEI route of administration or me-
mantine target dose did not explain the high heterogeneity
of the pooled results on cognition and behavioural and psy-
chological symptoms.
Discussion
In this meta-analysis of eight trials comparing combination
therapy with AChEI monotherapy in patients with mod-
erate to severe Alzheimer’s disease, combination therapy
had significantly greater effects on cognition and clinical
global impression at short-term follow-up, but not on be-
havioural and psychological symptoms. There was no ev-
idence that combination therapy in comparison to AChEI
monotherapy increased the risk of adverse events. Evi-
dence on nursing home placement and outcomes reported
at long-term follow-up was, in general, sparse. The overall
quality of evidence at short- and long-term follow-up was
very low. In most of the included trials, memantine was
added to ongoing AChEI therapy, which is in line with the
standard treatment course.
For the comparison of combination therapy versus meman-
tine monotherapy, we could include only two trials. The
overall quality of evidence for this comparison was very
low at short- and long-term follow-up.
Although the effects of combination therapy compared to
AChEI monotherapy on cognition and clinical global im-
pression were statistically significant, they were small and
their clinical relevance remains unclear. On a standardised
scale, as a rule of thumb, an effect size of 0.2 may be con-
sidered a small clinically relevant effect [39, 40]. Hence,
the effect estimates for cognition (SMD 0.20, 95% CI 0.05
Figure 6: Adverse events.
Figure 7: Withdrawals from study.
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to 0.35) and clinical global impression (SMD −0.15, 95%
CI −0.28 to −0.01) included the possibility of such an ef-
fect. The clinical relevance of the small effects would be
difficult to interpret even if they were reported on an origi-
nal scale, and there is – to our knowledge – no current con-
sensus regarding clinically relevant differences between
treatment groups for these outcomes. Similarly, the effects
of memantine monotherapy and particularly AChEI
monotherapy compared to placebo have been reported to
be small as well, and their clinical relevance has been
questioned repeatedly, especially when put into relation
with potential harms [4, 5, 41–47]. A possible approach
that might facilitate the interpretation of the small effects
would be to compare treatment response rates [48], based
on pre-defined clinically relevant differences, i.e. “mini-
mal clinically important difference (MCID).” Importantly,
MCIDs represent the clinically important difference for an
individual patient and therefore cannot be used to directly
judge the clinical relevance of group differences [49]. Due
to the degenerative nature of the disease, a dementia pa-
tient may be considered to be a treatment responder if the
outcome measures remain stable over a clinically relevant
follow-up period. To our knowledge, a consensus on rele-
vant MCIDs for the different outcomes still needs to be es-
tablished, even though some authors in the literature have
proposed cut-offs for MCIDs for cognition [49, 50]. One of
the two included RCTs that mentioned response rates, the
EXPECT 2011 trial, did not pre-define MCIDs and finally
did not report the response rates for their study population.
The other RCT, Tariot 2004, reported the response rates for
global impression, but for no other outcome. We consider
the available evidence from these responder analyses and
safety (see next paragraph) too sparse to support the inter-
pretation of clinical relevance. The clinical relevance of the
effects of combination therapy compared with monothera-
py therefore remains unclear.
For the comparison of combination therapy with AChEI
monotherapy, only four studies reported the number of pa-
tients that experienced an adverse event; hence, the small
beneficial effects cannot be weighed against the potential
harm. There was no evidence that the risk of adverse
events was higher for combination therapy than for AChEI
monotherapy. Adverse events frequently occur during the
titration period of AChEI. For the comparison of combi-
nation therapy with AChEI monotherapy, most RCTs in-
cluded patients who had already been on a stable dose of
AChEI. Hence, adverse events that had occurred before
study recruitment did not appear in the study reports and
patients who did not tolerate AChEIs were already exclud-
ed. Consequently, our findings are more likely to reflect
the adverse event profile of memantine added to ongoing
AChEI therapy.
Evidence on patient-relevant outcomes such as nursing
home placement was very limited. Nursing home place-
ment was judged to be a critical outcome, because it is a
proxy for the patient’s ability to live in his or her home
environment with or without health care support [50]. The
delay of nursing home placement may vary between differ-
ent health care systems and depends on the availability of
ambulatory care, cultural aspects, services to support fam-
ilies, institutional care facilities and financial resources.
Due to these factors, it should be interpreted in conjunction
with direct measures of function that reflect a patient’s
ability to maintain independence. In this context, quality of
life was rarely reported. This may be due to the difficul-
ty of assessing quality of life from a patient’s perspective
in Alzheimer’s disease due to progressing disease [51] and
expected systematic underestimation of the patient’s quali-
ty of life by the caregivers [52].
This is the most up-to-date and comprehensive review of
the evidence on combination therapy in patients with mod-
erate to severe Alzheimer’s disease, and is the only review
which has systematically assessed nursing home place-
ment and quality of life. We are aware of several recently
published systematic reviews that addressed a similar
question. In brief, these reviews either did not include rel-
evant RCTs that were available at the time when their
review was conducted [11], included patients with mild
Alzheimer’s disease [12] for which memantine is not ap-
proved or were limited to a single AChEI, namely
donepezil, and hence a substance comparison [13]. Anoth-
er systematic review, Kishi 2017 [53], primarily assessed
the efficacy of memantine in patients with mild to se-
vere Alzheimer’s disease. Kishi 2017 conducted subgroup
analyses for moderate to severe Alzheimer’s disease and
reported an effect estimate very similar to ours in this sub-
group for cognition (SMD 0.17, 95% CI 0.03 to 0.31). In
contrast to our findings, however, they reported a signif-
icant difference in behavioural and psychological symp-
toms of dementia (SMD 0.33, 95% CI 0.09 to 0.57). Kishi
2017 included two Japanese and one Chinese trial in this
sub-group analysis, whereas they did not include EXPECT
2011 and Porsteinsson 2008; this might explain the dis-
crepancy of the findings for the outcome behavioural and
psychological symptoms of dementia compared to the pre-
sent analysis. These Chinese or Japanese trials were not in-
dexed in EMBASE, Medline or CENTRAL when we con-
ducted our search, and we were unable to retrieve them. It
is unclear how the inclusion of these studies would have
affected our pooled effect estimates. Whereas the Chinese
study [54] and one [55] of the two Japanese studies were
relatively small (n = 32 and n = 35 patients) and probably
would have had only little effect, the other Japanese study
[56] (Nakamura 2016) would have been fairly large (n =
546). However, Kishi 2017 reported the effect of the Naka-
mura 2016 trial on cognition to be SMD 0.10, 95% CI 0.07
to 0.27. While Nakamura 2016 would have increased the
power of our analysis, the effect largely overlaps with our
pooled effect estimate. This would have resulted in a more
precise effect estimate, but probably differing only margin-
ally from our result.
A recently published extensive network meta-analysis on
110 RCTs by Tricco et al 2018 [57] reported the combina-
tion of donepezil with memantine as superior to donepezil
alone for the outcome of behaviour (measured with the
Neuropsychiatric Inventory [NPI]) (MD −3.9, 95% CI
−7.23 to −0.56; 26 RCTs with 5138 patients, 7 nodes, 6
treatments and placebo) or galantamine alone (MD −4.17,
95% credible intervals −7.97 to −0.29; 26 RCTs with 5138
patients, 7 nodes, 6 treatments and placebo). Tricco 2018
found no significant differences for the other outcomes or
for the comparison with memantine monotherapy. Final-
ly, around half of the included 110 RCTs were done on
patients with mild to moderate Alzheimer’s disease and
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it remains unclear how this affected the analysis. In our
meta-analysis, we report behavioural and psychological
symptoms of six RCTs as SMD because the studies used
different NPI scales. However, if we do not standardise the
mean difference, the resulting MD (−3.07, 95% CI −6.53
to 0.38) is similar to the MDs reported by Tricco 2018.
Our systematic review has limitations, which mainly relate
to the study limitations of the included RCTs: (1) Attrition
rates in the individual RCTs were high and most studies
used “last observation carried forward (LOCF)” for the
intention-to-treat analysis. Given that dementia is a pro-
gressive disease, results based on LOCF analysis seem in-
appropriate [58]. The number of withdrawals in AChEI
monotherapy was slightly higher and we addressed miss-
ing data with LOCF. This may have shifted the effect in
favour of AChEI monotherapy, and we may therefore have
underestimated the combination therapy’s effect. (2) Our
pooled results are limited because heterogeneity among
studies was high and remained unexplained because too
few studies were available for proper sub-group or sensi-
tivity analyses. (3) Applied instruments like the MMSE or
Alzheimer’s Disease Assessment Scale, cognitive subscale
(ADAS-Cog) are known to be less sensitive for severe de-
mentia because of floor effects [38] and may captured im-
precisely the differences in treatment effects the further
Alzheimer’s disease progressed. (4) Publication bias was
not detected. v) Seven of the nine included RCTs were in-
dustry sponsored. Finally, we were unable to consider all
available evidence because we could not retrieve one larg-
er [56] and two smaller trials [54, 55].
Future researchers should consider conducting an individ-
ual patient data (IPD) meta-analysis, which would allow
them (1) to perform post-hoc responder analyses based on
MCIDs, which still need to be established, (2) to use accu-
rate imputation methods (instead of LOCF) and (3) to as-
sess heterogeneity among trials with subgroups analyses.
However, all study authors would need to agree to share
their trial data. Future RCTs should report on function-
al outcomes and clearly define how they will assess the
clinical relevance (e.g. responder analyses). Further, they
should investigate time to nursing home placement and as-
sure complete safety reporting.
Trials with promising new agents (idalopirdine or intepir-
dine) have been stopped prematurely because of lack of
benefit [59, 60], and although more than 28 Alzheimer’s
disease agents are currently in phase III [61], the autho-
rised pharmaceutical therapies are limited to AChEI, me-
mantine and its combination. This highlights the impor-
tance of investigating the added benefit of the combination
of the two authorised and widely administered therapies
with well-designed RCTs with long-term follow-up.
To conclude, combination therapy compared to AChEI
monotherapy showed statistically significant effects for
cognition and clinical global impression at short term fol-
low-up. The clinical relevance of these effects is uncertain.
We have judged the overall quality of evidence to be very
low, mainly because of unexplained heterogeneity among
the included RCTs and inappropriate accounting in the
analysis for the high attrition rates. The sparse available
data for critical outcomes, the poor reporting of adverse
events and evidence mainly based on short-term follow-
up data highlight the need for large, investigator-initiated,
pragmatic RCTs with long-term follow-up.
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